Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab with Radiotherapy in Muscle-invasive Bladder Cancer
NCT04186013Phase 2Active, not recruiting
- Sponsor
- SOGUG
- Start
- Sep 2019
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of atezolizumab in muscle-invasive bladder cancer (MIBC), sponsored by SOGUG. Primary endpoint: Pathological Complete Response at 16 weeks. Started Sep 2019; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT04186013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04186013.